Keep an eye on your patients' vision
Medical innovation at the service of vision
OdySight® is a Class I medical device, CE certified in accordance with European Directive 93/42/EEC (MDD). With a commitment to the transition to the European Medical Device Regulation (MDR), OdySight® embodies innovation and compliance at the service of healthcare professionals and their patients.
The solution that optimizes the care pathway
Early detection
Our solution helps you to rapidly detect changes in visual acuity or damage to the second eye, enabling you to optimize your patients' care in line with the recommendations of the French National Authority for Health.
Accessibility and autonomy
OdySight® creates a link between doctor and patient, facilitating access to care. It encourages patients to take charge of their visual health through regular follow-up at home.
Patient engagement
The app rewards your patients with points for access to fun puzzles. Visual acuity monitoring becomes fun and easy to integrate into their routine.
For monitoring near visual acuity
Our remote monitoring solution supports more than 20,000 patients suffering from maculopathy or at risk of developing macular edema or neovascularization.
The most frequently identified pathologies are* :
Exudative AMD
Geographical atrophy
Drusen/MLA/DMLA intermediate
Severe myopia
Diabetic macular edema
Retinal vein occlusion
SCCR
Other causes of choroidal neovascularization or macular edema
OdySight®, clinically validated
Our solution is based on solid scientific results:
- Clinical studies conducted by Tilak Healthcare (developer of OdySight®) such as TIL001, TIL002 and TIL003
- Independent studies by renowned experts such as Dr. Guigou and Dr. Kielwasser.
Tilak Healthcare is committed to the continuous evaluation and improvement of its solutions, guaranteeing that its technology always meets medical requirements.
Keep in touch with your patients
1000
ophthalmologists
already offer OdySight® to their patients in France*.
72 %
ophthalmologists
report a positive difference in care**.
6000
patients
are active every month*.
1
injection / day
was administered following an OdySight® notification in 2024*.
*Sources: Tilak Healthcare internal data, September 2024. ** Sources: OdySight® Article 51 final report. IQVIA quantitative survey of 46 healthcare professionals.
Dr. Quaranta
Retinologist, Rabelais Center, Lyon
Join the 1,000 ophthalmologists already prescribing
Financed by Social Security
Since May 2022, OdySight® has been financed in France by the Social Security system as part of the Article 51 experiment. This scheme is a first step towards reimbursement under ordinary law, and enables the use of OdySight® to be financed by the doctors who prescribe the application. This is the first time in Europe that a remote ophthalmology monitoring application has been financed by a healthcare system.
They talk about us
Contact us
If you are a healthcare professional and would like to find out more about the OdySight® solution, please contact us.